IRLA.US IRulya Therapeutics Inc.

Healthcare Biotechnology USA Stocks
39.80 USD
Close of Nov 15, 2026
15.10 910.00
Market cap
USD 431M
P/E
-
P/B
2.21x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is IRLA.US undervalued?

Graham number

The Graham number of IRulya Therapeutics Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

IRulya Therapeutics Inc. fundamental analysis

No fundamental analysis for IRulya Therapeutics Inc. yet.

IRulya Therapeutics Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About IRulya Therapeutics Inc.

IRulya Therapeutics Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidate comprises eDSP, which is in Phase 3 for the treatment of rare pediatric neurodegenerative diseases, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in the ATM gene. Its AIDE technology platform is a drug/devi…

Full company profile